NetworkNewsBreaks – Vivos Therapeutics Inc.’s
Post# of 51
(Total Views: 155)
Posted On: 10/13/2021 3:16:40 PM
NetworkNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Guides Demonstrate Significant Reduction of Pediatric Tooth Decay in Peer-Reviewed Study
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing treatment using the company’s FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device. A preformed positioner intended to prevent a child’s teeth from shifting and may seal the lips to convert mouth breathing to nose breathing, the Vivos Guide is worn according to specific protocols as children sleep for 8-10 hours each day. “Mouth breathing has long been associated with an increase in cavities. That treatment with our Guide appliances has now been shown to significantly decrease pediatric cavities is a strong indication that they also work to establish proper nasal breathing and function,” said Kirk Huntsman, Vivos chairman and CEO. “The late Dr. Christian Guilleminault of Stanford University once said, ‘The restoration of nasal breathing…may be the only valid endpoint to treating OSA.’ Clearly, any time a treatment such as our Guides can help restore and promote nasal breathing, other positive health benefits tend to happen, and these study results prove that out with respect to lowering the risk of tooth decay in children. With the global dental fillings market size valued larger than US$5 billion, we are pleased show published, peer-reviewed data demonstrating the efficacy of the Vivos Guides and significant benefits the Guides may have on pediatric dental health.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing treatment using the company’s FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device. A preformed positioner intended to prevent a child’s teeth from shifting and may seal the lips to convert mouth breathing to nose breathing, the Vivos Guide is worn according to specific protocols as children sleep for 8-10 hours each day. “Mouth breathing has long been associated with an increase in cavities. That treatment with our Guide appliances has now been shown to significantly decrease pediatric cavities is a strong indication that they also work to establish proper nasal breathing and function,” said Kirk Huntsman, Vivos chairman and CEO. “The late Dr. Christian Guilleminault of Stanford University once said, ‘The restoration of nasal breathing…may be the only valid endpoint to treating OSA.’ Clearly, any time a treatment such as our Guides can help restore and promote nasal breathing, other positive health benefits tend to happen, and these study results prove that out with respect to lowering the risk of tooth decay in children. With the global dental fillings market size valued larger than US$5 billion, we are pleased show published, peer-reviewed data demonstrating the efficacy of the Vivos Guides and significant benefits the Guides may have on pediatric dental health.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Vivos Therapeutics Inc. (VVOS) Stock Research Links
Scroll down for more posts ▼